Titan Medical Inc (TMDIF)

[pontiacg6]

Chris Cleary Right above the M&A Attorney’s Signature

Medtronic has a history of placing large bets on technology that must go through the FDA’s stringent pre-market approval program, then basking in massive returns on those bets by assuming a market leadership position once the product wins PMA, Cleary explained, pointing to Medtronic’s acquisition of CoreValve as a prototypical Medtronic move.

Chris is Vice President of Corporate Development for Medtronic, with responsibility for acquisitions, dispositions and minority investments. During 2014, Chris led the corporate development efforts for Medtronic’s $50B acquisition of Covidien as well for Medtronic’s acquisition of both Sapiens and NGC, for $200MM and $350MM respectively.

Priorto 2014, Chris was CEO of Alesia Capital Services, a management consulting firm for Fortune 500 companies, including Medtronic, Goldman Sachs, Ally, Macquarie Capital and Terex. From 1995 to 2011, Chris led M&A teams within several businesses at GE Capital, closing acquisitions totaling more than $60B across 200+ transactions in the US, Canada, Europe, Asia and Latin America.

https://www.massdevice.com/inside-medtronic-covidien-deal-contrasting-styles-brought-companies-together/